{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:36:39Z","timestamp":1791819399066,"version":"4.3.4"},"reference-count":65,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Identification of new disease-associated biomarkers; specific targeting of such markers by monoclonal antibodies (mAbs); and application of advances in recombinant technology, including the production of humanized and fully human antibodies, has enabled many improved treatment outcomes and successful new biological treatments of some diseases previously neglected or with poor prognoses. Of the 110 mAbs preparations currently approved by the FDA and\/or EMA, 46 (including 13 antibody\u2013drug conjugates) recognizing 29 different targets are indicated for the treatment of cancers, and 66, recognizing 48 different targets, are indicated for non-cancer disorders. Despite their specific targeting with the expected accompanying reduced collateral damage for normal healthy non-involved cells, mAbs, may cause types I (anaphylaxis, urticaria), II (e.g., hemolytic anemia, possibly early-onset neutropenia), III (serum sickness, pneumonitis), and IV (Stevens\u2013Johnson syndrome, toxic epidermal necrolysis) hypersensitivities as well as other cutaneous, pulmonary, cardiac, and liver adverse events. MAbs can provoke severe infusion reactions that resemble anaphylaxis and induce a number of systemic, potentially life-threatening syndromes with low frequency. A common feature of most of these syndromes is the release of a cascade of cytokines associated with inflammatory and immunological processes. Epidermal growth factor receptor-targeted antibodies may provoke papulopustular and mucocutaneous eruptions that are not immune-mediated.<\/jats:p>","DOI":"10.3390\/antib11010017","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T20:46:17Z","timestamp":1645994777000},"page":"17","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-4865","authenticated-orcid":false,"given":"Brian A.","family":"Baldo","sequence":"first","affiliation":[{"name":"Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, Sydney, NSW 2065, Australia"},{"name":"Department of Medicine, University of Sydney, Sydney, NSW 2065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ossipow, V., and Fischer, N. (2014). Methods and protocols. Method in Molecular Biology, Humana Press. [2nd ed.].","DOI":"10.1007\/978-1-62703-992-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Baldo, B.A. (2016). Safety of Biologics Therapy: Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins, Springer Nature.","DOI":"10.1007\/978-3-319-30472-4"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijbiomac.2019.06.006","article-title":"Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies","volume":"135","author":"Kumar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_5","unstructured":"Kaur, H., and Reusch, D. (2021). Monoclonal antibodies. Physicochemical Analysis, Academic Press."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.it.2021.10.008","article-title":"Single B cell technologies for monoclonal antibody discovery","volume":"42","author":"Pedrioli","year":"2021","journal-title":"Trends Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2741\/2749","article-title":"Human antibodies: A race to engineer and explore a larger diversity","volume":"13","author":"Mondon","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_8","unstructured":"Food and Drug Administration (2021, December 14). Rare Diseases: Common Issues in Drug Development Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-common-issues-drug-development-guidance-industry."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-019-1017-5","article-title":"Regulatory strategies for rare diseases under current global regulatory statutes: A discussion with stakeholders","volume":"14","author":"Mulberg","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.iac.2014.04.003","article-title":"Adverse events to nontargeted and targeted chemotherapeutic agents","volume":"34","author":"Baldo","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_11","first-page":"1619","article-title":"Humanization of antibodies","volume":"13","author":"Almagro","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106639","DOI":"10.1016\/j.intimp.2020.106639","article-title":"Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives","volume":"85","author":"Parray","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_13","unstructured":"Lemtrada (alemtuzumab) (2021, December 14). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103948s5158lbl.pdf."},{"key":"ref_14","unstructured":"Campath (alemtuzumab) (2021, December 14). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103948s5070lbl.pdf."},{"key":"ref_15","unstructured":"Prolia (denosumab) (2021, December 14). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125320s205lbl.pdf."},{"key":"ref_16","unstructured":"Xgeva (denosumab) (2021, December 14). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Baldo, B.A., and Pham, N.H. (2021). Drug Allergy: Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships, Springer Nature. [2nd ed.].","DOI":"10.1007\/978-3-030-51740-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e26333","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy. Focus on hypersensitivity responses","volume":"2","author":"Baldo","year":"2013","journal-title":"OncoImmunology"},{"key":"ref_20","first-page":"668","article-title":"Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses","volume":"85","author":"Stephens","year":"1995","journal-title":"Immunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_22","first-page":"266","article-title":"NAVIGATOR: A phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate Nthe efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"13","author":"Colice","year":"2020","journal-title":"Respir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Corren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V99.6.2054","article-title":"Thrombocytopenia after second exposure to abciximab-coated platelets","volume":"9","author":"Curtis","year":"2002","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/107424840200700i103","article-title":"Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro)","volume":"7","author":"Sharma","year":"2002","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1352458518816612","article-title":"Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management","volume":"26","author":"Cuker","year":"2020","journal-title":"Mult. Scler. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/imt-2021-0163","article-title":"Alemtuzumab induced red cell aplasia and other immune cytopenias\u2014Not so \u2018pure\u2019","volume":"14","author":"Aitken","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"P2.103","DOI":"10.1212\/WNL.86.16_supplement.P2.103","article-title":"Fatal autoimmune hemolytic anemia associated with alemtuzumab in a MS patient with severe relapsing remitting disease course and prior immune therapies (P2.103)","volume":"86","author":"Reickmann","year":"2016","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2018-99-112724","article-title":"Severe Coombs positive autoimmune hemolytic anemia after alemtuzumab infusion for relapsing remitting multiple sclerosis. What can we learn?","volume":"132","author":"Desai","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/1042819021000055110","article-title":"Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder","volume":"44","author":"Jourdan","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_33","first-page":"CS133","article-title":"Rituximab-associated neutropenia: Description of three cases and an insight into the underlying pathogenesis","volume":"17","author":"Brenner","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"CS85","DOI":"10.12659\/MSM.881838","article-title":"Severe thrombocytopenia related to trastuzumab infusion","volume":"17","author":"Mantzourani","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1445-5994.2005.00899.x","article-title":"Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis","volume":"35","author":"Anandacoomarasamy","year":"2005","journal-title":"Intern. Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archderm.142.2.246","article-title":"Rituximab-induced leukocytoclastic vasculitis: A case report","volume":"142","author":"Kandula","year":"2006","journal-title":"Arch. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1346-8138.2009.00639.x","article-title":"Rituximab-induced vasculitis: A case report and review of the medical published work","volume":"36","author":"Kim","year":"2009","journal-title":"J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"Mannik","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdg488","article-title":"Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment","volume":"14","author":"Hellerstedt","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.rhu.0000262585.18582.1e","article-title":"Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia","volume":"13","author":"Finger","year":"2007","journal-title":"J. Clin.Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/MJT.0000000000001139","article-title":"Acute pneumonitis due to nivolumab and ipilimumab combination","volume":"29","author":"Mir","year":"2022","journal-title":"Am. J. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: From clinical data to translational investigation","volume":"10","author":"Zhu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: A systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JOP.18.00143","article-title":"Managing infusion reactions to new monoclonal antibodies in multiple myeloma: Daratumumab and elotuzumab","volume":"14","author":"Nooka","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Huang, A., Xu, Y., Zang, X., Wu, C., Gao, J., Sun, X., Xie, M., Ma, X., Deng, H., and Song, J. (2021). Beigelman-Aubry, C. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08353-y"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"00165","DOI":"10.1183\/23120541.00165-2019","article-title":"Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: A retrospective study","volume":"6","author":"Pozzessere","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: A systematic literature review","volume":"35","author":"Mayaud","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4049\/jimmunol.1402513","article-title":"The acute respiratory distress syndrome: From mechanism to translation","volume":"194","author":"Han","year":"2015","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1378\/chest.08-2408","article-title":"Activation and regulation of systemic inflammation in ARDS: Rationale for prolonged glucocorticoid therapy","volume":"136","author":"Meduri","year":"2009","journal-title":"Chest"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e27987","DOI":"10.4161\/onci.27987","article-title":"Adverse cardiac events to monoclonal antibodies used for cancer therapy","volume":"3","author":"Kounis","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-9966-31-50","article-title":"Chemotherapy and skin reactions","volume":"31","author":"Fabbrocini","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"key":"ref_57","unstructured":"Thapa, S., and Shrestha, U. (2021, December 14). Immune Reconstitution Inflammatory Syndrome, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567803\/."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.02.016","article-title":"Macrophage activation syndrome: A new complication of checkpoint inhibitors","volume":"77","author":"Malissen","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0031-1277990","article-title":"Posterior reversible encephalopathy syndrome: A review","volume":"31","author":"Feske","year":"2011","journal-title":"Semin. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/0003-4819-153-2-201007200-00005","article-title":"Narrative review: The systemic capillary leak syndrome","volume":"153","author":"Druey","year":"2010","journal-title":"Annals Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJMoa1415236","article-title":"Systemic inflammatory response syndrome criteria in defining severe sepsis","volume":"372","author":"Kaukonen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MABS"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/11\/1\/17\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:27:55Z","timestamp":1760135275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/11\/1\/17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["antib11010017"],"URL":"https:\/\/doi.org\/10.3390\/antib11010017","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}